脉络膜新生血管
黄斑变性
视网膜色素上皮
视网膜
医学
抗氧化剂
新生血管
药理学
氧化应激
氧化损伤
视网膜
视网膜变性
玻璃体内给药
PEDF公司
眼底(子宫)
不利影响
眼科
癌症研究
细胞损伤
贝伐单抗
化学
作者
Yifan Zhou,Mei‐Yan Xu,Y Xu,An Shao,Wenyu Cui,Wenyue Shen,Yingcheng He,Zhichu Chen,Y Zhang,Qi Miao,Haijie Han,Juan Ye
出处
期刊:ACS Nano
[American Chemical Society]
日期:2026-04-29
卷期号:20 (18): 13663-13681
标识
DOI:10.1021/acsnano.6c00302
摘要
Oxidative stress-induced retinal pigment epithelium (RPE) damage and ferroptosis are critical in retinal degenerative diseases, particularly in age-related macular degeneration (AMD)─a major cause of irreversible blindness. Current clinical AMD treatment is predominantly dependent on intravitreal anti-VEGF administration targeting only late-stage choroidal neovascularization (CNV), with limitations of incomplete response and adverse effects. Herein, a facile synthesis of Nuci@PAM-BR, which was designed by modification of antioxidant bilirubin to the surface and encapsulation of antiferroptosis nuciferine in the hydrophobic cavity of polyamidoamine dendrimers, was reported, thus achieving iron homeostasis restoration via triple-pool-targeted scavenging properties for eradicating CNV in AMD management. Our results demonstrated that Nuci@PAM-BR could significantly attenuate CNV by targeting the detrimental "triple pool" in damaged RPE cells, exhibiting excellent antioxidant and anti-inflammatory properties that contributed to its excellent antiangiogenic effect, achieving an over 80% reduction in leakage area and an over 85% decline in neovascular lesion. Such triple-pool-targeted nanotherapy offers a promising alternative and holds significant potential for the future clinical treatment of diverse fundus neovascularization diseases, including AMD.
科研通智能强力驱动
Strongly Powered by AbleSci AI